Stefano Fiorucci

Q: What Schools Are Affiliated With Stefano Fiorucci

Stefano Fiorucci is affiliated with the following schools: University of Calgary, D'Annunzio University of Chieti–Pescara, University of Milan, University of Salerno, University of Perugia, Stanford University

Stefano Fiorucci's AcademicInfluence.com Rankings

Stefano Fiorucci

Physics

#6141

World Rank

#8048

Historical Rank

physics Degrees

Download Badge

Physics

Stefano Fiorucci's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Stefano Fiorucci Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stefano Fiorucci's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hydrogen sulfide is an endogenous modulator of leukocyte‐mediated inflammation (2006) (815)
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. (2002) (656)
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis (2005) (491)
The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity1 (2009) (460)
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. (2004) (411)
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. (2005) (403)
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. (2006) (364)
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats[S] (2010) (350)
Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. (2015) (312)
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. (2009) (292)
The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis (2011) (283)
Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? (2001) (282)
Evidence That Hydrogen Sulfide Exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels (2006) (254)
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. (2007) (251)
Bile Acids Activated Receptors Regulate Innate Immunity (2018) (248)
Galectin-1 suppresses experimental colitis in mice. (2003) (247)
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. (2016) (243)
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. (2003) (234)
Enhanced activity of a hydrogen sulphide‐releasing derivative of mesalamine (ATB‐429) in a mouse model of colitis (2007) (204)
Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis (2001) (195)
Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. (1994) (194)
Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis (2005) (186)
Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP (2014) (178)
Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. (1999) (176)
Endothelial nitric oxide synthase: the Cinderella of inflammation? (2003) (173)
Targeting farnesoid X receptor for liver and metabolic disorders. (2007) (173)
Galectin‐1 exerts immunomodulatory and protective effects on concanavalin a–induced hepatitis in mice (2000) (172)
The bile acid sensor FXR regulates insulin transcription and secretion. (2010) (170)
Antiatherosclerotic effect of farnesoid X receptor. (2009) (166)
A Farnesoid X Receptor-Small Heterodimer Partner Regulatory Cascade Modulates Tissue Metalloproteinase Inhibitor-1 and Matrix Metalloprotease Expression in Hepatic Stellate Cells and Promotes Resolution of Liver Fibrosis (2005) (166)
The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo (2006) (164)
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. (2004) (162)
The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis (2017) (160)
PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation (2004) (160)
A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. (2004) (157)
Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor γ Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis (2005) (155)
Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. (1995) (152)
5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity (2006) (147)
PPARs and other nuclear receptors in inflammation. (2006) (142)
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. (2002) (136)
Potential cardioprotective actions of no-releasing aspirin (2002) (135)
Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice. (1996) (131)
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension (2001) (130)
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. (2010) (126)
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa (2003) (121)
The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis1 (2009) (121)
NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. (2000) (110)
Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice (2013) (108)
Importance of Innate Immunity and Collagen Binding Integrin α1β1 in TNBS-Induced Colitis (2002) (103)
Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. (1999) (102)
Farnesoid X receptor: from structure to potential clinical applications. (2005) (101)
IL-1β Converting Enzyme Is a Target for Nitric Oxide-Releasing Aspirin: New Insights in the Antiinflammatory Mechanism of Nitric Oxide-Releasing Nonsteroidal Antiinflammatory Drugs (2000) (101)
Role of FXR in regulating bile acid homeostasis and relevance for human diseases. (2005) (97)
NO‐naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis (2000) (97)
Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome (2013) (96)
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation (2012) (93)
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity (2001) (93)
A role for proteinase-activated receptor-1 in inflammatory bowel diseases. (2004) (92)
NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. (2007) (91)
Counter-regulatory role of bile acid activated receptors in immunity and inflammation. (2010) (90)
Inhibition of Intestinal Bacterial Translocation with Rifaximin Modulates Lamina propria Monocytic Cells Reactivity and Protects against Inflammation in a Rodent Model of Colitis (2003) (90)
FXR an emerging therapeutic target for the treatment of atherosclerosis (2009) (88)
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis (2017) (87)
Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. (2011) (85)
Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue Activation (2011) (81)
Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells (1995) (80)
The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation (2013) (80)
Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. (2010) (79)
The Methyl Transferase PRMT1 Functions as Co-Activator of Farnesoid X Receptor (FXR)/9-cis Retinoid X Receptor and Regulates Transcription of FXR Responsive Genes (2005) (78)
The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. (2009) (77)
Mechanism of non-steroidal anti-inflammatory drug-gastropathy. (2001) (77)
NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. (2003) (76)
Disruption of an SP2/KLF6 Repression Complex by SHP Is Required for Farnesoid X Receptor-induced Endothelial Cell Migration* (2006) (73)
Relative contribution of acetylated cyclooxygenase (COX)‐2 and 5‐lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin (2003) (72)
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. (2011) (71)
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. (2014) (71)
In vivo activated T cells in rheumatoid synovitis. Analysis of Th1‐ and Th2‐type cytokine production at clonal level in different stages of disease (2002) (69)
Quantitative NMR-derived interproton distances combined with quantum mechanical calculations of 13C chemical shifts in the stereochemical determination of conicasterol F, a nuclear receptor ligand from Theonella swinhoei. (2012) (69)
Nitric Oxide—Releasing NSAIDs (2001) (68)
NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice (2002) (67)
Bile acids and their receptors in metabolic disorders. (2021) (67)
Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. (2011) (64)
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. (2014) (63)
Proteinase‐activated Receptor‐1 is an Anti‐Inflammatory Signal for Colitis Mediated by a Type 2 Immune Response (2005) (62)
Bile Acid Signaling in Inflammatory Bowel Diseases (2020) (62)
Farnesoid X receptor modulators 2014-present: a patent review (2018) (62)
A magic bullet for mucosal protection...and aspirin is the trigger! (2003) (61)
Gastric acidity and gastroesophageal reflux patterns in patients with esophagitis. (1992) (60)
The methionine connection: Homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats (2007) (60)
Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. (2011) (59)
Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity (2017) (58)
21‐NO‐prednisolone is a novel nitric oxide‐releasing derivative of prednisolone with enhanced anti‐inflammatory properties (2000) (58)
Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis (2012) (58)
Evidence that 5‐lipoxygenase and acetylated cyclooxygenase 2‐derived eicosanoids regulate leukocyte–endothelial adherence in response to aspirin (2003) (58)
Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. (2011) (56)
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). (2014) (56)
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. (2011) (56)
Diabetic Mouse Angiopathy Is Linked to Progressive Sympathetic Receptor Deletion Coupled to an Enhanced Caveolin-1 Expression (2004) (55)
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. (2010) (55)
Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. (2000) (54)
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. (2009) (54)
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition (2012) (53)
Inhibition of Chronic Ulcerative Colitis-associated Adenocarcinoma Development in Mice by VSL#3 (2015) (52)
The Pharmacology of Bile Acids and Their Receptors. (2019) (52)
Primary brain abscess with Nocardia farcinica in an immunocompetent patient (2002) (52)
NCX-4016 (NO-Aspirin) Inhibits Lipopolysaccharide-Induced Tissue Factor Expression In Vivo: Role of Nitric Oxide (2002) (52)
Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. (2003) (52)
Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia (2002) (52)
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. (2002) (51)
Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain (2020) (51)
Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1 (2015) (50)
Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. (1994) (50)
Role of PAR2 in pain and inflammation. (2002) (50)
Farnesoid X receptor agonists in biliary tract disease (2009) (50)
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. (2004) (50)
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. (2019) (49)
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. (2013) (49)
The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines (2016) (48)
Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. (1998) (48)
Aspirin-Triggered, Cyclooxygenase-2–Dependent Lipoxin Synthesis Modulates Vascular Tone (2004) (48)
Dissociation of Intestinal and Hepatic Activities of FXR and LXRα Supports Metabolic Effects of Terminal Ileum Interposition in Rodents (2013) (48)
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. (2011) (48)
Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO‐pegylated epirubicin (2006) (47)
Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. (1994) (47)
Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. (2011) (47)
NO-releasing NSAIDs are caspase inhibitors. (2001) (46)
Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. (2013) (46)
Future trends in the treatment of non‐alcoholic steatohepatitis (2018) (46)
Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages. (2009) (45)
Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids. (2015) (44)
Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. (2006) (44)
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) (2020) (44)
Plakilactones from the marine sponge Plakinastrella mamillaris. Discovery of a new class of marine ligands of peroxisome proliferator-activated receptor γ. (2012) (44)
Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. (2004) (43)
Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei. (2012) (43)
Marine sponge steroids as nuclear receptor ligands. (2012) (43)
Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice. (2015) (42)
NO-aspirin: mechanism of action and gastrointestinal safety. (2003) (42)
Polarization of the α6β4 integrin in ovarian carcinomas (1993) (42)
Targeting FXR in cholestasis: hype or hope (2014) (42)
Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. (2012) (41)
Role of Nuclear Receptors in Lipid Dysfunction and Obesity-Related Diseases (2013) (41)
Selective endoscopic retrograde cholangiography and preoperative bile duct stone removal in patients scheduled for laparoscopic cholecystectomy: a prospective study. (1996) (41)
Circadian variations in gastric acid and pepsin secretion and intragastric bile acid in patients with reflux esophagitis and in healthy controls. (1995) (40)
Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling (2015) (40)
NCX‐4016, a nitric oxide‐releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function (2002) (40)
Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis (2016) (40)
Essential requirement for sphingosine kinase activity in eNOS‐dependent NO release and vasorelaxation (2006) (40)
Hydrogen sulphide induces μ opioid receptor-dependent analgesia in a rodent model of visceral pain (2010) (40)
A NO‐releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway  THIS ARTICLE HAS BEEN RETRACTED (2002) (39)
Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists (2016) (39)
Farnesoid X receptor: from medicinal chemistry to clinical applications. (2012) (38)
SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts (2011) (38)
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation (2004) (37)
4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity (2012) (37)
Proteinase-Activated Receptor-2 Mediates Arterial Vasodilation in Diabetes (2005) (36)
Anti-Very Late Antigen-1 Monoclonal Antibody Modulates the Development of Secondary Lesion and T-Cell Response in Experimental Arthritis (2000) (35)
Cooperation between Aspirin-Triggered Lipoxin and Nitric Oxide (NO) Mediates Antiadhesive Properties of 2-(Acetyloxy)benzoic Acid 3-(Nitrooxymethyl)phenyl Ester (NCX-4016) (NO-Aspirin) on Neutrophil-Endothelial Cell Adherence (2004) (35)
Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice (2017) (33)
Oxygenated Polyketides from Plakinastrella mamillaris as a New Chemotype of PXR Agonists (2013) (33)
Towards new ligands of nuclear receptors. Discovery of malaitasterol A, an unique bis-secosterol from marine sponge Theonella swinhoei. (2011) (32)
Receptor-ligand interactions: Advanced biomedical applications. (2016) (32)
NO-NSAIDs: from inflammatory mediators to clinical readouts. (2006) (32)
Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators. (2017) (32)
The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice (2010) (31)
Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated withHelicobacter pylori infection and high levels of serum pepsinogens (1995) (31)
Activation of the farnesoid‐X receptor protects against gastrointestinal injury caused by non‐steroidal anti‐inflammatory drugs in mice (2011) (30)
Nitric Oxide (NO)-Releasing Naproxen (HCT-3012 [(S)-6-Methoxy-α-methyl-2-naphthaleneacetic Acid 4-(Nitrooxy)butyl Ester]) Interactions with Aspirin in Gastric Mucosa of Arthritic Rats Reveal a Role for Aspirin-Triggered Lipoxin, Prostaglandins, and NO in Gastric Protection (2004) (30)
COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. (2011) (30)
Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis (2018) (30)
Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. (2015) (30)
Liver delivery of NO by NCX‐1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice  THIS ARTICLE HAS BEEN RETRACTED (2004) (29)
Nitric Oxide Regulates Immune Cell Bioenergetic: A Mechanism to Understand Immunomodulatory Functions of Nitric Oxide-Releasing Anti-Inflammatory Drugs (2004) (29)
NSAIDs upregulate β2‐integrin expression on human neutrophils through a calcium‐dependent pathway (1997) (29)
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity. (2013) (29)
Nitric oxide modulates pepsinogen secretion induced by calcium-mediated agonist in guinea pig gastric chief cells. (1995) (28)
Chenodeoxycholic Acid: An Update on Its Therapeutic Applications. (2019) (28)
Hydrogen sulfide-based therapies: focus on H2S releasing NSAIDs. (2011) (28)
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice (2007) (27)
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. (2019) (27)
Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future. (2009) (26)
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. (2003) (26)
BLOOD GLUCOSE TESTING AND FEDERAL REGULATIONS (1991) (26)
GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis (2019) (25)
Solomonsterol A, a Marine Pregnane-X-Receptor Agonist, Attenuates Inflammation and Immune Dysfunction in a Mouse Model of Arthritis (2013) (25)
Bombesin-induced pancreatic regeneration in pigs is mediated by p46Shc/p52Shc and p42/p44 mitogen-activated protein kinase upregulation. (1998) (25)
Polyhydroxylated sterols from the Indonesian soft coral Sinularia sp. and their effect on farnesoid X-activated receptor (2012) (25)
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa (2015) (25)
Epidermal growth factor modulates pepsinogen secretion in guinea pig gastric chief cells. (1996) (25)
Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism (2015) (25)
Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. (2003) (25)
Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite. (2019) (24)
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury. (2018) (23)
Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders. (2020) (23)
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases (2017) (23)
Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists (2017) (23)
The HIV Matrix Protein p17 Subverts Nuclear Receptors Expression and Induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes (2012) (23)
Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties (2019) (23)
Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. (1989) (23)
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. (2006) (23)
Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitis. (2005) (23)
Unveiling hidden features of orphan nuclear receptors: the case of the small heterodimer partner (SHP). (2006) (23)
Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy (1990) (23)
Erythromycin stimulates gallbladder emptying and motilin release by atropine-sensitive pathways (1992) (22)
Effect of erythromycin on gallbladder emptying in diabetic patients with and without autonomic neuropathy and high levels of motilin (1992) (21)
Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. (2004) (21)
Farnesoid X receptor modulators (2011 – 2014): a patent review (2015) (21)
PAR-2 modulates pepsinogen secretion from gastric-isolated chief cells. (2003) (21)
NO-mesalamine protects colonic epithelial cells against apoptotic damage induced by proinflammatory cytokines. (2001) (21)
Disruption of TFG&bgr;‐SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand (2018) (21)
The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions (2019) (21)
Leukotrienes stimulate pepsinogen secretion from guinea pig gastric chief cells by a nitric oxide-dependent pathway. (1995) (21)
Salicylates Inhibit T Cell Adhesion on Endothelium Under Nonstatic Conditions: Induction of L-Selectin Shedding by a Tyrosine Kinase-Dependent Mechanism (2001) (21)
Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists. (2019) (21)
Ritonavir-Induced Lipoatrophy and Dyslipidaemia is Reversed by the Anti-Inflammatory Drug Leflunomide in a Ppar-Γ-Dependent Manner (2012) (20)
Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region (2020) (20)
Isolated guinea pig gastric chief cells express tumour necrosis factor receptors coupled with the sphingomyelin pathway. (1996) (20)
Bile Acids Activated Receptors in Inflammatory Bowel Disease (2021) (20)
Gynecomastia during omeprazole therapy. (1991) (20)
Enhanced Anti-Inflammatory Potency of a Nitric Oxide-Releasing Derivative of Flunisolide: Role of Nuclear Factor-κB (2004) (20)
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate. (2011) (19)
Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells. (1998) (19)
Modification in the side chain of solomonsterol A: discovery of cholestan disulfate as a potent pregnane-X-receptor agonist. (2012) (19)
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. (2020) (19)
Cyclo-oxygenase isoenzymes. Structural basis for selective inhibition of cyclo-oxygenases by anti-inflammatory agents. (2001) (19)
Pathogenesis of non-steroidal anti-inflammatory drug gastropathy. (1999) (19)
HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes (2012) (18)
Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. (2012) (18)
A role for proteinase-activated receptor-1 in inflammatory bowel diseases. (2004) (18)
Molecular decodification of gymnemic acids from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists (2015) (18)
Phallusiasterols A and B: Two New Sulfated Sterols from the Mediterranean Tunicate Phallusia fumigata and Their Effects as Modulators of the PXR Receptor (2014) (17)
Bazedoxifene-scaffold-based mimetics of solomonsterols A and B as novel pregnane X receptor antagonists. (2014) (17)
FENSAP-ICE Applications to Unmanned Aerial Vehicles (UAV) (2004) (17)
Preliminary Structure-Activity Relationship on Theonellasterol, a New Chemotype of FXR Antagonist, from the Marine Sponge Theonella swinhoei (2012) (17)
Helicobacter pylori and non-steroidal anti-inflammatory drugs. (2000) (17)
Polarization of the alpha 6 beta 4 integrin in ovarian carcinomas. (1993) (17)
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non‐steroidal anti‐inflammatory drugs and aspirin in mice (2013) (17)
Farnesoid X Receptor: From Structure to Potential Clinical Applications (2005) (17)
The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity (2020) (16)
The First Total Synthesis of Solomonsterol B, a Marine Pregnane X Receptor Agonist (2012) (16)
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation (2019) (15)
Gene expression changes induced by HIPEC in a murine model of gastric cancer. (2012) (15)
Epigenetic Modulation by Methionine Deficiency Attenuates the Potential for Gastric Cancer Cell Dissemination (2012) (15)
Inhibition of NF-kB by a PXR-Dependent Pathway Mediates Counter-regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells (2011) (15)
Lipoxins in gastric mucosal health & disease (2005) (15)
Type III procollagen peptide and PZ-peptidase serum levels in pre-cirrhotic liver diseases. (1985) (14)
Oesophageal lesions during treatment with piroxicam. (1990) (14)
Insights on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges. (2014) (14)
Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity (2016) (14)
Structural insights into Estrogen Related Receptor-β modulation: 4-Methylenesterols from Theonella swinhoei sponge as the first example of marine natural antagonists (2014) (14)
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. (2013) (14)
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. (2009) (14)
Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands (2016) (13)
Effect of NSAIDs on pepsinogen secretion and calcium mobilization in isolated chief cells. (1995) (13)
Synthesis and characterization of well-defined poly(2-deoxy-2-methacrylamido-d-glucose) and its biopotential block copolymers via RAFT and ROP polymerization (2018) (13)
Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1 (2019) (13)
Isoswinholide B and swinholide K, potently cytotoxic dimeric macrolides from Theonella swinhoei. (2013) (13)
Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities (2019) (13)
Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis. (1990) (13)
Motilin and erythromycin stimulate pepsinogen secretion by chief cells isolated from guinea pig stomach. (1993) (12)
New brominated flame retardants and their metabolites as activators of the pregnane X receptor. (2016) (12)
Gastrin-releasing peptide directly releases pepsinogen from guinea pig chief cells. (1990) (12)
Abscess formation in hepatocellular carcinoma: Complications of percutaneous ultrasound‐guided ethanol injection (1993) (12)
Marine and Semi-Synthetic Hydroxysteroids as New Scaffolds for Pregnane X Receptor Modulation (2014) (12)
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction (2021) (12)
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases. (2017) (11)
Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. (2016) (11)
Anti‐Inflammatory Activity of a New Class of Nitric Oxide Synthase Inhibitors That Release Nitric Oxide (2008) (11)
l-Arginine/nitric oxide pathway modulates gastric motility and gallbladder emptying induced by erythromycin and liquid meal in humans (1995) (11)
Placebo-controlled comparison of piroxicam-β-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans (1992) (11)
Chalinulasterol, a Chlorinated Steroid Disulfate from the Caribbean Sponge Chalinula molitba. Evaluation of Its Role as PXR Receptor Modulator (2012) (11)
Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists (2014) (11)
Nanotraps with biomimetic surface as decoys for chemokines. (2017) (11)
Linking liver metabolic and vascular disease via bile acid signaling. (2021) (10)
Lipoxins in gastric mucosal health and disease. (2005) (10)
The HIV Matrix Protein p17 Promotes the Activation of Human Hepatic Stellate Cells through Interactions with CXCR2 and Syndecan-2 (2014) (10)
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis (2017) (10)
Hydrogen sulfide: from physiology to pharmacology. (2011) (10)
The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease (2021) (10)
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy (2020) (10)
Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis. (1989) (9)
New tridecapeptides of the theonellapeptolide family from the Indonesian sponge Theonella swinhoei (2013) (9)
5-Hydroxytryptamine 3-receptor antagonist modulates gallbladder emptying and motilin release induced by erythromycin (1993) (9)
Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C. (2012) (9)
Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential (2021) (9)
Duodenal osmolality drives gallbladder emptying in humans (1990) (9)
Amphiphilic polypeptides with prolonged enzymatic stability for the preparation of self-assembled nanobiomaterials (2018) (9)
Intragastric pH monitoring during antisecretory therapy in patient with gastrointestinal bleeding. (1989) (9)
PATHOGENESIS OF NSAID GASTROPATHY (1999) (9)
Gastric Tolerance of Piroxicam-β-Cyclodextrin Compared with Placebo and with Other NSAIDs (1990) (9)
Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease (2021) (8)
Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients? (1988) (7)
Control of gastric pH with ranitidine in critically Ill patients (1991) (7)
Proteinase‐activated receptors (PARs) and immune function (2003) (7)
Immunomodulatory functions of FXR (2022) (7)
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma (2015) (7)
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling (2021) (7)
Dual COX-inhibitors: the answer is NO? (2005) (6)
Celecoxib exacerbates gastrointestinal damage induced by aspirin but not by no-aspirin (NCX-4016): A randomised, parallel group, blind-observer endoscopic study. Evidence for a protective role of no in the gastrointestinal mucosa (2003) (6)
Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics (2021) (6)
Special FX: Harnessing the Farnesoid-X-Receptor to Control Bile Acid Synthesis (2021) (6)
Effect of HCT1026, a nitric oxide (NO) releasing derivative of flurbiprofen on gastrointestinal mucosa: a double blind placebo-controlled endoscopic study (2003) (5)
GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis. (2020) (5)
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation (2020) (5)
Phallusiasterol C, A New Disulfated Steroid from the Mediterranean Tunicate Phallusia fumigata (2016) (5)
Prostaglandin E2 desensitizes cAMP-mediated pepsinogen secretion in chief cells. (1991) (5)
Anti-atherosclerotic effect of Farnesoid-X-Receptor in ApoE -/- mice (2008) (4)
Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1. (2020) (4)
Tumor necrosis factor α receptor-antagonists protect against indomethacin-induced gastric mucosal injury in rats (1995) (4)
Erratum (Retracted article): A role for proteinase-activated receptor-1 in inflammatory bowel diseases (Journal of Clinical Investigation (2004) 114 (1444-1456) DOI:10.1172/JCI200421689) (2006) (4)
3α-6α-Dihydroxy-7α-fluoro-5β-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17α-ethynyl-estradiol-induced cholestasis in rats (2006) (4)
Diethylstilbestrol-scaffold-based pregnane X receptor modulators. (2015) (4)
Epoxide functionalization on cholane side chains in the identification of G-protein coupled bile acid receptor (GPBAR1) selective agonists (2017) (4)
Mechanistic Role of p38 MAPK in Gastric Cancer Dissemination in a Rodent Model Peritoneal Metastasis (2011) (3)
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation (2022) (3)
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. (2022) (3)
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis (2022) (3)
Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties (2019) (3)
FXR Promotes Adipocyte Differentiation and regulates adipose cell function in vivo (2006) (3)
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. (2014) (3)
Su1053 - Bar704, a Potent and Selective Fxr Agonist Protects Against Intestinal Fibrosis (2018) (2)
3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats. (2006) (2)
A new protective mechanisn in NSAID gastropathy. Evidence that hydrogen sulfide (H2S) modulates gastric mucosal integrity (2005) (2)
Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases (2018) (2)
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma (2022) (2)
Estimation of the Mechanical Parameters for a Reduced Coupled Flexural–Torsional Beam Model of a Tall Building by a Sub-Structure Approach (2021) (2)
M1735 FXR Activation Reverses Insulin Resistance and Protects Against NASH Development (2009) (2)
SNK @ DANKMEMES: Leveraging Pretrained Embeddings for Multimodal Meme Detection (short paper) (2020) (2)
Prevention of gastric damage by no-releasing aspirin (NCX-4016) is mediated by inhibition of ICE/-like proteases in gastric mucosa and endothelial cells (1998) (2)
Bile acid metabolism and bile acid receptor signaling in metabolic diseases and therapy (2021) (2)
Cephalic stimulation of gallbladder motility: effects of opioid receptor antagonist naloxone (1988) (2)
Correction: The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis (2013) (2)
Sa1959 Instruction of Intestinal Microbiota by VSL#3 Protects Against NSAIDs-PPI Enteropathy (2013) (1)
Tu1111: REGULATION OF INTESTINAL ACE2 EXPRESSION BY THE BILE ACID RECEPTOR GPBAR1 IS MEDIATED BY A GPBAR1/GLP-1/GLP-1R AXIS (2022) (1)
Organoids as ex vivo culture system to investigate infection-host interaction in gastric pre-carcinogenesis. (2022) (1)
[Healing of esophageal ulcer after treatment with omeprazole in a patient with scleroderma and Barrett's esophagus]. (1988) (1)
GPBAR1 (TGR5) Ligation Protects Against Colitis Development by Regulating Leukocyte Traffinking and Promoting a IL-10 Dependent Shift in the M1/M2 Phenotype (2017) (1)
Inverse Virtual Screening for the rapid re-evaluation of the presumed biological safe profile of natural products. The case of steviol from Stevia rebaudiana glycosides on farnesoid X receptor (FXR). (2021) (1)
Editorial [Hot Topic: Nitric Oxide and Lipoxins: Role in Inflammation and Defence (Guest Editor: Stefano Fiorucci)] (2006) (1)
The FXR-agonist, 6-ethyl-chenodeoxycholic acid (6-ECDCA), protects against estrogen-induced cholestasis in rats (2003) (1)
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease (2022) (1)
NO-NSAID gastrointestinal safety is related to inhibition of ICE-like Cysteine Proteases. New insights into the moleculare basis of NSAID gastropathy (1998) (1)
Biodegradability of inhaled organic particles in patients with chronic bronchitis. (1987) (1)
[Diagnostic effectiveness of immunoreactive serum trypsinogen, pancreatic iso-amylase and lipase in the diagnosis of acute pancreatic injury in hyperamylasemic patients]. (1986) (1)
Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis. (2011) (1)
Editorial [Hot Topic :Current Advances In Therapeutic Applications of Nuclear Receptors (Guest Editor: Stefano Fiorucci)] (2012) (1)
773 The Bile Acid Sensor FXR Modulates Hydrogen Sulfide Generation in the Gastric Mucosa and Protects Against Injury Caused by Aspirin (2010) (1)
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1. (2021) (1)
M1739 Ml3403, a New p38 MAPK Inhibitor, Corrects Immune Dysfunction in Rodent Models of Chronic Inflammatory Disorders (2010) (1)
M1802 Rifaximin is a Human Pregnane X Receptor Activator in Human Colon Epithelial Cells and Regulate Detoxification Pathway (2010) (1)
the Bile Acid Sensor FXR Induces the Glucocorticoid Receptor in the Liver in a Promoter-Dependent Manner (2011) (1)
Current advances in therapeutic applications of nuclear receptors. (2012) (1)
Variability in Industrial Production Affects Probiotics Activity: Identification of Batches of Probiotic VSL#3 that Increases Intestinal Permeability and Worsens Colitis in Rodents (2017) (1)
TRPM8 indicates poor prognosis in colorectal cancer patients and its pharmacological targeting reduces tumour growth in mice by inhibiting Wnt/β‐catenin signalling (2022) (1)
ATB-429 , a hydrogen sulfide-releasing derivative of mesalamine , exerts anti-nociceptive effects in a model of post-inflammatory hypersensitivity (2006) (1)
Hyperglycemia Decreases the Erythromycin-induced Gallbladder Emptying and Motilin Release In Normal Subjects (1994) (0)
A novel, hydrogen sulfide-releasing mesalamine derivative (ATB-429) exhibits enhanced anti-inflammatory and analgesic activity in experimental colitis: O-0010 (2007) (0)
IL-1 b Converting Enzyme Is a Target for Nitric Oxide-Releasing Aspirin: New Insights in the Antiinflammatory Mechanism of Nitric Oxide-Releasing Nonsteroidal Antiinflammatory Drugs (2000) (0)
NO-Aspirin (NCX-4016) prevents platelet and monocyte activation inducing less gastric damage compared to aspirin (2004) (0)
Role of mRAGEs and ACE2 in SARS-CoV-2-Related Inflammation. (2022) (0)
Nitric oxide-derived NSAIDs inhibit ICE-like cysteine proteases, IL-1 beta and IFN gamma release and protect from Concanavallin A-induced acute liver injury. (1998) (0)
Bombesin (BB) stimulates angiogenesis in large mammalian pancreas and MAPK activity and proliferation on endothelial cells (1998) (0)
Effect of bombesin on pancreatic regeneration after subtotal distal pancreasectomy. (1997) (0)
Tu2051 The HIV Matrix Protein P17 Subverts the Nuclear Receptor Transcriptome in HEPG2 Cells (2013) (0)
Treatment strategy of hepatocellular carcinoma: Comparison between percutaneous ethanol injection and radiofrequency ablation, a three-year follow-up study (2003) (0)
RNAseq analysis HFD mice (2019) (0)
BAR130, a Hyodeoxycholic Acid Derivative as the First Example of Dual LXRα/GPBAR1 Agonist (2017) (0)
The crosstalk between gut barrier impairment, mitochondrial dysfunction, and microbiota alterations in people living with HIV (2022) (0)
NO-NSAIDs are ICE/caspase1 inhibitors and protect from citokine-mediated acute liver failure induced by Concanavalin A in mice. (1999) (0)
Sa1587 A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis (2016) (0)
Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists (2023) (0)
Marine natural products as modulators of nuclear receptors (2012) (0)
Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis (2011) (0)
EGF modulates pepsinogen secretion by activating multiple intracellular pathway in gastric isolated chief cells. (1996) (0)
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma (2023) (0)
Modulation of the nuclear receptor for farnesoidi (fxr) with agonists molecules for the prevention and treatment of atherosclerotic phenomena induced by administration of protease inhibitors (2010) (0)
Transcriptomic analysis of a mouse model of Acetaminophen-induced hepatitis (2019) (0)
Mo1353: DEVELOPMENT OF A DUAL GPBAR1 AND CYSTLTR1 MODULATOR TO PREVENT HEPATIC DAMAGE AND LIVER FIBROSIS (2022) (0)
Molecular Determinants of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Model of Peritoneal Gastric Cancer Carcinogenesis (2011) (0)
Effect of NO donors and NO-aspirin on TNF release and gastric mucosal damage in rats and isolated macrophages (1997) (0)
GDF15 in Vascular and Liver Metabolic Disorders: A Novel Therapeutic Target. (2022) (0)
Discovery of Bar704, A Potent and Selective FXR Agonist, that Protects Against Liver Fibrosis (2017) (0)
Metagenomic analysis in a mouse model of steatohepatitis (2019) (0)
Bile acid derivatives as FXR ligands for the prevention or treatment of diseases or conditions mediated by FXR (2007) (0)
Tu2041 Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE-/- Mice (2012) (0)
Bombesin-induced pancreatic regeneration in rats is age-dependent (1998) (0)
Galectin-1 protects against concanavalin a-induced liver injury by preventing T cell activation. (1999) (0)
Notice of Retraction: ‘A NO‐releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway’ (Br J Pharmacol 135; 589–599; 2002) (2009) (0)
Development of Effective and Safe Analgesic and Anti-Inflammatory Drugs: Harnessing Natural Substances for Clinical Solutions. (2021) (0)
Mo2014 – Comparative Effects of Bar502, a Dual Fxr and Gpbar1 Agonist, Obeticholic Acid and Ursodeoxycholic Acid in a Rodent Model of Nash (2019) (0)
Tu1738 - The Aryl Hydrocarbon Receptor Mediates Anti-Inflammatory Activities of Natural and Synthetic Pelargonidines in Mouse Models of Colitis (2018) (0)
1009 Epigenetic Modulation of Adhesion and Proliferation Pathways by Methionine Deficiency Attenuates Potential for Dissemination of Gastric Cancer Cells (2012) (0)
Tu1417 Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation (2012) (0)
Coupled to an Enhanced Caveolin-1 Expression Diabetic Mouse Angiopathy Is Linked to Progressive Sympathetic Receptor Deletion (2004) (0)
Su1733 The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs (2012) (0)
4 P Dual cyclo-lipo-oxygenase inhibition spares the gastric mucosa in aspirin treated rats (2002) (0)
Procede de reduction d'effets secondaires indesirables induits par un medicament chez un patient (2005) (0)
T1965 Bile Acids Induce Rat PPARγ2 Gene via Activation of Farnesoid X Receptor. (2010) (0)
How smell regulates metabolism: The role of ectopically expressed olfactory receptors in lipid and glucose homeostasis (2022) (0)
Oxide-Releasing Anti-Inflammatory Drugs Immunomodulatory Functions of Nitric Bioenergetic: A Mechanism to Understand Nitric Oxide Regulates Immune Cell (2004) (0)
2 - GPBAR1 (TGR5) Agonism Reverses Endothelial Dysfunction and Liver Injury in a Dietetic Model of Steatohepatitis (2018) (0)
Preventing Integrin Activation Induced by Contact With Endothelial Cells Salicylates Inhibit Adhesion and Transmigration of T Lymphocytes by (2013) (0)
Discovery of a AhR flavonoid agonist that counter-regulates ACE2 expression in rodent models of inflammation and attenuates ACE2-SARS-CoV2 interaction in vitro (2021) (0)
Mo1915 Genetic Ablation and Pharmacological Blockade of CCR5 by the anti-HIV Small Molecule Inhibitor Maraviroc Inhibits Leukocyte Trafficking and Protects Against Mucosal Inflammation in Murine Models Colitis (2016) (0)
Proteinase activated receptor (PAR)-2 protects against colitis in mice. Evidence for direct modulation of lamina propria T lymphocytes (2001) (0)
The CCR5 antagonist maraviroc reduces the potential for gastric cancer dissemination in rodent models (2013) (0)
16 A Dark Side of FXR Activation in Cholestasis. FXR Is a Negative Regulator of MRP4 (2009) (0)
Molecular Docking and Dynamics Simulation Studies of a Dataset of NLRP3 In-flammasome Inhibitors (2022) (0)
Penthoxyfilline Protects Against Indomethacin-induced Acute Gastric-mucosal Damage In Rats (1993) (0)
Stimulation of small intestine chemoreceptors activates rectal afferent pathways in IBS patients (2000) (0)
Tu1748 - Probiotics Beyond Taxonomy: Evidence that Anti-inflammatory Properties of Live Biotherapeutic Products Require Phenotypic Characterization (2018) (0)
The methyl trasnferase PRMT1 functions as coactivator of FXR/RXR and regulates transcription of FXR responsive genein hepatocytes (2004) (0)
Tu1828 GPBAR1(TGR5) Is Highly Expressed in Human Gastric Cancers and Its Activation by Selective or GPBAR1/FXR Dual Ligands Promotes Epithelial Mesenchymal Transition and Tumor Spreading (2016) (0)
Aroleforproteinase-activatedreceptor-1ininflammatoryboweldiseases (2006) (0)
Tu1920 a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation (2012) (0)
8 OP Rifaximin protects against colitis development by reducing local immuneu response to bacterial antigen (2002) (0)
Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders (2023) (0)
of Intestinal Innate Immunity The Bile Acid Receptor FXR Is a Modulator (2009) (0)
1079 Macrolide Derivatives Devoid of Antibiotic Activity Correct Immune Dysfunction in Rodent Models of Inflammatory Bowel Diseases. (2010) (0)
Safety and Anti-Inflammatory Effects of a Hydrogen ulfide – Releasing Diclofenac Derivative in the Rat (0)
Co-administration of NO-Aspirin (NCX-4016) and Aspirin prevents platelet and monocyte activation and protects against damage induced by aspirin in humans. (2004) (0)
Type two of proteinase activated receptors (PAR-2) protects against colitis through a CGRP-dependent pathway (2000) (0)
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury. (2022) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
825 BAR502, a Dual FXR and GPBAR1 Agonist, Reverses Steatosis and Fibrosis in Rodent Model of NASH By Modulating Authophagic Genes (2016) (0)
BAR501, A Selective Gpbar1 Agonist, Promotes Adipose Tissue Browning and Autophagy and Improves Lipid Metabolism and Steato-Hepatitis in Mice Feed a High Fat Diet (2017) (0)
Tu2023 A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors. (2013) (0)
[Pharmacologic effect of a new synthetic analog of somatostatin (SMS 201-995) on fasting intragastric pH in subjects with duodenal ulcer]. (1988) (0)
Tu1546 – Gpbar1 is a Modulator of Liver Immunity and Its Agonism Reverses Acetaminophen-Induced Hepatotoxicity by Modulating Recruitment of Liver Macrophages (2019) (0)
Modeling inflammatory bowel disease by intestinal organoids. (2022) (0)
Transcriptomic analysis of Human gastric cancer (2020) (0)
A Hydrogen‐Sulfide Releasing Derivative of Mesalamine Exhibits Markedly Enhanced Anti‐Inflammatory Effects in Experimental Colitis (2007) (0)
[Nonsurgical treatment of hemorrhage caused by esophageal varices]. (1988) (0)
Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1 (2019) (0)
1108 Reciprocal Regulation of TLRS and Nuclear Receptors: IRF-7 Dependent Regulation of FXR Mediates Counter-Regulatory Effects of TLR-9 in Colitis (2012) (0)
NCX-1000: a liver-specific NO donor (2004) (0)
604 H2S Induces Analgesia Is Mediated In Vivo Activation of μ Opioid Receptor and PI3K/AKT Pathway Activation (2009) (0)
Farnesoid-X-receptor (FXR) ligands induce a small heterodimer partner (SHP)-dependent upregulation of PPAR-gamma in hepatic stellate cells and in rat model of liver fibrosis. (2004) (0)
Sa1541: DISCOVERY OF A NOVEL CYSTEINYL-LEUKOTRIENE-RECEPTOR 1 ANTAGONIST AND BILE ACID RECEPTOR GPBAR1 AGONIST THAT REDUCES INFLAMMATION IN A MOUSE MODEL OF COLITIS (2022) (0)
Bisphenol AF: Does bisphenol AF glucuronide have endocrine activity? (2017) (0)
Model of Acute Hepatitis a Modulator of Liver Immunity in a Rodent The Bile Acid Sensor Farnesoid X Receptor Is (2009) (0)
Su2132 Dissociation of Activity of Ileal and Liver FXR Mediates Metabolic Effects in a Rodent Model of Bariatric Surgery. (2013) (0)
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH (2023) (0)
Recombinant galectin-1 prevents experimental colitis in mice via T cell apoptosis (2000) (0)
An NO-derivative of acetaminophen, NCX-701, spares the liver by inhibiting fasdependent apoptosis (2001) (0)
NCX-1000, an NO derivative of UDCA, refeases NO and protects against portal hypertension by inhibiting hepatic stellate cell contraction (2001) (0)
the Ritonavir pro-atherogenetic activity prevention by PPAR alpha agonist in ApoE-/-mice is mediated by CD36 (2010) (0)
NO-Releasing NSAIDs Modulate Cytokine Secretion (2001) (0)
S2070 FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis (2009) (0)
Subject Index Vol. 66, 2002 (2003) (0)
241 - GPBAR1 (TGR5) is a Modulator of Liver Immunity and Reverses Liver Inflammation in a Mouse Models of Acute Hepatitis (2018) (0)
Nitric oxide protects against HIV gp120 endothelial injury (2010) (0)
An no-derivative of ursodeoxycholic acid exerts anti-apoptotic effects by inhibiting fas-dependent activation of liver (2000) (0)
Tyrosine Kinase-Dependent Mechanism Induction of L-Selectin Shedding by a Endothelium Under Nonstatic Conditions: Salicylates Inhibit T Cell Adhesion on (2000) (0)
Gastrointestinal safety and anti-inflammatory activity of HCT-1026, NO-releasing flurbiprofen, in healthy humans volunteers (2004) (0)
Treatment of Fibrosis with FXR ligands. (2005) (0)
Contents Vol. 66, 2002 (2002) (0)
Sections Vol. 66, 2002 (2003) (0)
Nitric oxide modulates pepsinogen secretion induced by Ca2+-mediated agents by isolated chief cells. (1995) (0)
Rescuing inflammation By Inflammasome Inhibitors. (2022) (0)
Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice (2017) (0)
11 P An no-derivative of UDCA (NCX-1000) modulates the dinamic component of intrahepatic resistance in a rat model of liver chirrosis (2002) (0)
The Bile Acids Receptor TGR5 is an Essential Modulator of Intestinal Membrane Permeability and Exerts Anti-Inflammatory Activities in Rodent Model of Colitis (2011) (0)
Nitric Oxide-derived NSAIDs inhibit ICE-like Cysteine Proteasis and protect from acute liver injury in a mice model of T-cell mediated hepatitis (1998) (0)
[Effects of TRH and secretin on serum output of immunoreactive trypsin: evidence of a direct inhibitory mechanism]. (1987) (0)
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs (2011) (0)
The vagal control of gallbladder motility is impaired in diabetics with autonomic neuropathy. (1990) (0)
Discovery of gymnemic acids as a new class of liver X receptor antagonists (2015) (0)
Editorial [Hot Topic: Hydrogen Sulfide: From Molecular Biology to Pharmacology Guest Editor: Stefano Fiorucci)] (2011) (0)
Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced (2012) (0)
Protective effects of granulocyte macrophage colony stimulating factor (gm-Csf) in Hapten-induced colitis (2005) (0)
Helicobacter p ylori and non-steroidal anti-inflammatory drugs (2000) (0)
Mo1916 BAR 501, a Novel GPBAR1 Ligand, Reverses Intestinal and Liver Inflammatory Models Demonstrating That GPBAR1 Is an Essential Modulator of Innate Immunity in Entero-Hepatic Tissues (2016) (0)
Function of CD44 variant isoforms in human T cell. (1994) (0)
Nitric oxide inhibits hepatic stellate cell dependent tumor angiogenesis in primary and metastatic liver cancer (2005) (0)
Tu1304: ROLE OF A DUAL GPBAR1/CYSLT1R MODULATOR REVERSES LIVER INJURY AND FIBROSIS IN A RODENT MODEL OF NASH (2022) (0)
Analysis of oral and gut microbiota in children with dental cavities by Ion torrent 16s rRNA sequencing (2021) (0)
Notice of Retraction: ‘Liver delivery of NO by NCX‐1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice’ (Br J Pharmacol 143; 33–42; 2004) (2009) (0)
COX-2 selective inhibitors cause gastric damage in aspirin treated rats Protective effect of nitroaspirin (NCX-4016) (2001) (0)
An update in H(2)S in physiology, pathophysiology and pharmacology. (2011) (0)
Ultrasound and stomach (1994) (0)
Sa1518 – Mechanism of Acute Liver Decompensation Caused by Obeticholic Acid in Cholestasis is Fxr Dependent (2019) (0)
[Control using omeprazole in a case of upper digestive hemorrhage, induced by erosive uremic hemorrhagic gastritis resistant to conventional therapy]. (1989) (0)
542 Farnesoid X Receptor Regulates Glutamate Metabolism: Relevance for Hepatic Encephalopathy (2010) (0)
Farnesoid X Receptor Dependent Regulation of MMP9 in Blood Outgrowth Endothelial Cells (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stefano Fiorucci?

Stefano Fiorucci is affiliated with the following schools: